Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes

Virology

Volumn 270, Issue 2, 2000, Pages 254-257

  Roden, Richard B S ^a,b   Yutzy IV, William H ^b   Fallon, Rosemary ^c   Inglis, Stephen ^c   Lowy, Douglas R ^a   Schiller, John T ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Cantab Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; EPITOPE; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CROSS REACTION; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; SHEEP; STRAIN DIFFERENCE; VACCINE PRODUCTION; VIRUS NEUTRALIZATION; WART VIRUS;

ANIMALIA; DNA VIRUSES; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES; MIRIDAE; OVIS ARIES; PAPILLOMAVIRUS;

EID: 0034630951     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0272     Document Type: Article

References (22)

1. Breitburd F., Kirnbauer R., Hubbert N. L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., Schiller J. T., Lowy D. R. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69:1995;3959-3963.
2. Campo M. S., O'Neil B. W., Grindlay G. J., Curtis F., Knowles G., Chandrachud L. A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease. Virology. 234:1997;261-266.
3. Chandrachud L. M., Grindlay G. J., McGarvie G. M., O'Neil B. W., Wagner E. R., Jarrett W. F., Campo M. S. Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4. Virology. 211:1995;204-208.
4. Christensen N. D., Kreider J. W. Antibody-mediated neutralization in vivo of infectious papillomaviruses. J. Virol. 64:1990;3151-3156.
5. Christensen N. D., Kreider J. W., Kan N. C., DiAngelo S. L. The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology. 181:1991;572-579.
6. Gaukroger J. M., Chandrachud L. M., O'Neil B. W., Grindlay G. J., Knowles G., Campo M. S. Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies. J. Gen. Virol. 77:1996;1577-1583.
7. Human Papillomaviruses." "IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 1995;IARC, Lyon.
8. Jarrett W. F., Smith K. T., O'Neil B. W., Gaukroger J. M., Chandrachud L. M., Grindlay G. J., McGarvie G. M., Campo M. S. Studies on vaccination against papillomaviruses: Prophylactic and therapeutic vaccination with recombinant structural proteins. Virology. 184:1991;33-42.
9. Kawana K., Matsumoto K., Yoshikawa H., Taketani Y., Kawana T., Yoshiike K., Kanda T. A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2. Virology. 245:1998;353-359.
10. Kawana K., Yoshikawa H., Taketani Y., Yoshiike K., Kanda T. Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J. Virol. 73:1999;6188-6190.
11. Kirnbauer R., Chandrachud L. M., O'Neil B. W., Wagner E. R., Grindlay G. J., Armstrong A., McGarvie G. M., Schiller J. T., Lowy D. R., Campo M. S. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology. 219:1996;37-44.
12. Kirnbauer R., Taub J., Greenstone H., Roden R., Durst M., Gissmann L., Lowy D. R., Schiller J. T. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 67:1993;6929-6936.
13. Lacey C. J., Thompson H. S., Monteiro E. F., O'Neill T., Davies M. L., Holding F. P., Fallon R. E., Roberts J. S. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J. Infect. Dis. 179:1999;612-618.
14. Lin Y. L., Borenstein L. A., Selvakumar R., Ahmed R., Wettstein F. O. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology. 187:1992;612-619.
15. Liu W. J., Gissmann L., Sun X. Y., Kanjanahaluethai A., Muller M., Doorbar J., Zhou J. Sequence close to the N-terminus of L2 protein is displayed on the surface of bovine papillomavirus type 1 virions. Virology. 227:1997;474-483.
16. Roden R. B., Greenstone H. L., Kirnbauer R., Booy F. P., Jessie J., Lowy D. R., Schiller J. T. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J. Virol. 70:1996;5875-5883.
17. Roden R. B., Hubbert N. L., Kirnbauer R., Christensen N. D., Lowy D. R., Schiller J. T. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J. Virol. 70:1996;3298-3301.
18. Roden R. B., Weissinger E. M., Henderson D. W., Booy F., Kirnbauer R., Mushinski J. F., Lowy D. R., Schiller J. T. Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J. Virol. 68:1994;7570-7574.
19. Suzich J. A., Ghim S. J., Palmer-Hill F. J., White W. I., Tamura J. K., Bell J. A., Newsome J. A., Jenson A. B., Schlegel R. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA. 92:1995;11553-11557.
20. Trus B. L., Roden R. B., Greenstone H. L., Vrhel M., Schiller J. T., Booy F. P. Novel structural features of bovine papillomavirus capsid revealed by a three-dimensional reconstruction to 9 A resolution. Nature Struct. Biol. 4:1997;413-420.
21. Volpers C., Sapp M., Komly C. A., Richalet-Secordel P., Streeck R. E. Development of type-specific and cross-reactive serological probes for the minor capsid protein of human papillomavirus type 33. J. Virol. 67:1993;1927-1935.
22. Yaegashi N., Jenison S. A., Batra M., Galloway D. A. Human antibodies recognize multiple distinct type-specific and cross-reactive regions of the minor capsid proteins of human papillomavirus types 6 and 11. J. Virol. 66:1992;2008-2019.